Form 4: Singular Genomics CEO Andrew Spaventa Executes Stock Transactions Following RSU Vesting

Singular Genomics CEO Andrew Spaventa acquired and disposed of shares following the vesting of restricted stock units, including sales to cover tax obligations and gifts to a living trust.

Summary

• Andrew Spaventa, CEO of Singular Genomics, engaged in several transactions involving the company's stock on November 12, 2024.
• These transactions were triggered by the vesting of restricted stock units (RSUs).
• Mr. Spaventa acquired 1,907 shares upon the vesting of RSUs.
• He then sold 695 shares at $22.545 per share to cover tax obligations related to the vesting.
• Following the sale, Mr. Spaventa gifted 1,212 shares to The Andrew K. Spaventa Living Trust.
• Additionally, 1,212 shares were transferred to the trust as a gift.
• After these transactions, Mr. Spaventa directly owns 1,537 shares and indirectly owns 141,487 shares through The Andrew K. Spaventa Living Trust and 85 shares through Axon Holdings, LLC.
• The RSUs vest in 16 equal quarterly installments over four years from February 12, 2024.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation. There is no indication of positive or negative sentiment, it is a standard process.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It reflects the standard practice of granting stock-based compensation to executives and the subsequent transactions that occur upon vesting.

Comparison to Industry Standards

• The vesting schedule of RSUs over four years with quarterly installments is a common practice in the technology and biotech industries.
• The sale of shares to cover tax obligations is a standard procedure for executives receiving stock-based compensation.
• The use of a living trust for asset management is a common practice among high-net-worth individuals, including corporate executives.

Related Party Transactions

• The transfer of shares to The Andrew K. Spaventa Living Trust is a related party transaction.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are related to executive compensation and do not represent a significant change in ownership.
• The sale of shares to cover tax obligations may have a slight downward pressure on the stock price, but this is a common occurrence.

Key Dates

Keywords

Singular Genomics, Andrew Spaventa, stock transactions, restricted stock units, RSU, insider trading, beneficial ownership, SEC Form 4